Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Investments (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Long-Term Investments for 14 consecutive years, with $56.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments changed N/A year-over-year to $56.1 million, compared with a TTM value of $56.1 million through Dec 2025, changed N/A, and an annual FY2022 reading of $29.3 million, down 72.99% over the prior year.
  • Long-Term Investments was $56.1 million for Q4 2025 at Enanta Pharmaceuticals, up from $42.5 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $115.7 million in Q2 2021 and bottomed at $5.9 million in Q2 2023.
  • Average Long-Term Investments over 5 years is $49.6 million, with a median of $40.8 million recorded in 2022.
  • The sharpest move saw Long-Term Investments crashed 84.97% in 2023, then soared 617.59% in 2024.
  • Year by year, Long-Term Investments stood at $88.7 million in 2021, then plummeted by 69.62% to $26.9 million in 2022, then crashed by 78.01% to $5.9 million in 2023, then skyrocketed by 617.59% to $42.5 million in 2024, then soared by 31.86% to $56.1 million in 2025.
  • Business Quant data shows Long-Term Investments for ENTA at $56.1 million in Q4 2025, $42.5 million in Q2 2024, and $5.9 million in Q2 2023.